课题基金 / 基金详情

Analytical Performance And Clinical Utility Of Thyroid F

Analytical Performance And Clinical Utility Of Thyroid F
甲状腺 F 的分析性能和临床实用性
批准号:
6675221
负责人:
Gyorgy Csako
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Gyorgy Csako的其他基金

相似基金

相关文献

中文摘要
翻译
甲状腺疾病是最常见的内分泌异常,据估计,在美国,每年约有2000万左甲状腺素处方分发给1.8%的人口。因此,最佳地利用有效的实验室检查来评估甲状腺状况在医学上和经济上都是重要的。在一项多机构合作研究中,我们继续评估监测甲状腺功能测试的性能以及甲状腺激素治疗抑制乳头状和/或滤泡性甲状腺癌的潜在临床应用。以抑制血清促甲状腺激素(TSH)为目标的长期甲状腺激素治疗传统上用于治疗高分化甲状腺癌。然而,通过随机对照试验正式验证甲状腺激素抑制治疗的效果是缺乏的。此外,低环境浓度TSH对人甲状腺肿瘤发生的影响尚不清楚。我们从文献中确定了28项临床试验,这些试验涉及1934年至2001年间甲状腺癌患者使用甲状腺激素抑制治疗。应用李克特量表,17项“可解释”的研究中有15项显示甲状腺激素抑制治疗对甲状腺癌预后的有益影响“可能”或“可疑”。我们定量评估了甲状腺激素抑制治疗对主要不良临床事件(疾病进展/复发和死亡)可能性的影响,这些不良临床事件来自10项有资格进行荟萃分析的累积甲状腺癌队列研究。这10项研究共涉及4174例患者,其中2880例(69%)接受甲状腺激素抑制治疗。meta分析显示,接受甲状腺激素抑制治疗的患者组发生重大临床不良事件的风险降低(相对风险0.73,置信区间0.60-0.88,p < 0.05)。因此,尽管长期使用甲状腺激素有已知的不良反应,但在甲状腺癌患者中使用这些激素进行抑制治疗是合理的。需要能够检测极低TSH水平(至少低于0.10 mU/L,可能低于0.01 mU/L)的高灵敏度TSH测定来评估这些患者甲状腺激素抑制治疗的充分性。
英文摘要
Thyroid diseases represent the most common endocrine abnormalities and it has been estimated that about 20 million levothyroxine prescriptions are dispensed to about 1.8% of the population in the United States annually. Optimal use of valid laboratory tests for the assessment of thyroid status is thus important both medically and economically. In a multi-institute collaborative study, we continued to assess the performance of thyroid function tests for monitoring and the potential clinical utility of thyroid hormone therapy for suppressing papillary and/or follicular thyroid cancer. Long-term thyroid hormone therapy aiming at the suppression of serum thyrotropin (TSH) has been traditionally used in the management of well-differentiated thyroid cancer. However, formal validation of the effects of thyroid hormone suppression therapy through randomized controlled trials is lacking. Additionally, the effect of TSH at low ambient concentrations upon human thyroid tumorigenesis remains unclear. We identified 28 clinical trials from the literature that dealt with the use of thyroid hormone suppression therapy in patients with thyroid cancer between 1934 and 2001. Applying a likert scale, 15 of the17 "interpretable" studies showed either a "likely" or "questionable" beneficial effect of thyroid hormone suppression therapy on the outcome of thyroid cancer. We quantitatively evaluated the effect of thyroid hormone suppression therapy on the likelihood of major adverse clinical events (disease progression/recurrence and death) in a cumulative thyroid cancer cohort from 10 studies that qualified for meta-analysis. The 10 studies represented a combined total of 4,174 patients of whom 2,880 (69%) were reported as being on thyroid hormone suppression therapy. According to meta-analysis, the group of these patients with thyroid hormone suppression therapy had a decreased risk of major adverse clinical events (relative risk 0.73, confidence interval 0.60-0.88, p less than 0.05). Thus, despite the known adverse effects of long-term administration of thyroid hormones, suppression therapy with these hormones is justified in patients with thyroid cancer. High-sensitivity TSH assays that are capable of detecting very low TSH levels (at least less than 0.10 mU/L and, possibly, less than 0.01 mU/L) are needed to assess the adequacy of thyroid hormone suppression therapy in these patients. In another collaborative project, we analyzed the results of a pilot trial that evaluated the effects of extreme changes in thyroid hormone availability on serum lipids, lipoproteins, apolipoproteins, and on the hemostasis in thyroid cancer patients receiving thyroid hormone suppression therapy. Thyroid function tests, serum lipid parameters (with special respect to lipoprotein[a]) and various hemostatic parameters were assessed before, at, and after the time these patients were undergoing scanning. Better understanding of the relationship between thyroid hormones and the lipid and hemostatic system is important because hypothyroidism is known to be associated with elevated serum lipids and increased incidence of atherothrombotic events.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analytical and Clinical Studies on Factors Involved in Atherosclerosis
  • 批准号:
    6227894
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Gyorgy Csako
  • 依托单位:
Analytical Performance and Clinical Utility of Lab Tests for Study of Artherotho
  • 批准号:
    6431869
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Gyorgy Csako
  • 依托单位:
Analytical Performance/Clinical Utility Of Lab Tests
  • 批准号:
    7215829
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Gyorgy Csako
  • 依托单位:
Laboratory Testing for Endocrine Abnormalities
  • 批准号:
    7593107
  • 项目类别:
  • 资助金额:
    $1.4万
  • 财政年份:
    --
  • 负责人:
    Gyorgy Csako
  • 依托单位:
海外基金